Capricor Therapeutics (CAPR) EBT Margin (2011 - 2024)
Capricor Therapeutics' (CAPR) quarterly EBT Margin came in at 65.01% in Q4 2024, down 5373.0% year-on-year from 1.23% in Q1 2024, and up 98.88% quarter-over-quarter from 5794.83% in Q3 2024.
Capricor Therapeutics (CAPR) EBT Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' EBT Margin history runs 13 years deep, the most recent figure standing at 65.01% for Q4 2024.
- On a quarterly basis, EBT Margin fell 5373.0% year-over-year to 65.01% in Q4 2024; TTM through Sep 2025 was 1622.12%, a 92726.0% decrease from a year earlier, with the FY2024 full-year figure at 181.7%, down 3697.0% from the prior year.
- EBT Margin climbed to 65.01% in Q4 2024 per CAPR's latest filing, from 5794.83% in the prior quarter.
- Across five years, EBT Margin topped out at 11.28% in Q4 2023 and bottomed at 71092.46% in Q3 2020.
- The 5-year median for EBT Margin is 968.75% (2020), against an average of 7873.7%.
- Across the five-year window, EBT Margin tumbled 6988160 bps in 2020 and surged 1879918 bps in 2021, its largest moves.
- Year by year, EBT Margin stood at 7229.02% in 2020, then soared by 66 bps to 2482.54% in 2021, then jumped by 69 bps to 768.91% in 2022, then jumped by 99 bps to 11.28% in 2023, then slumped by 476 bps to 65.01% in 2024.
- Per Business Quant, the three latest CAPR EBT Margin figures stand at 65.01% (Q4 2024), 5794.83% (Q3 2024), and 582.84% (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65.01% |
| Sep 30, 2024 | -5,794.83% |
| Jun 30, 2024 | -582.84% |
| Mar 31, 2024 | -412.24% |
| Dec 31, 2023 | -11.28% |
| Sep 30, 2023 | -171.74% |
| Jun 30, 2023 | -497.20% |
| Mar 31, 2023 | -275.46% |
| Dec 31, 2022 | -768.91% |
| Sep 30, 2022 | -1,523.03% |
| Jun 30, 2021 | -2,482.54% |
| Mar 31, 2021 | -12,622.31% |
| Dec 31, 2020 | -7,229.02% |
| Sep 30, 2020 | -71,092.46% |
| Jun 30, 2020 | -21,281.72% |
| Mar 31, 2020 | -1,168.58% |
| Dec 31, 2019 | -661.60% |
| Sep 30, 2019 | -1,210.86% |
| Jun 30, 2019 | -503.64% |
| Mar 31, 2019 | -1,308.05% |